Feb 15, 2022 11:30am EST Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Jan 21, 2022 8:00am EST Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Jan 20, 2022 8:00am EST JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY
Jan 18, 2022 11:51am EST Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Jan 05, 2022 4:05pm EST OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Dec 23, 2021 8:00am EST OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
Nov 29, 2021 10:25am EST BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.